Tamosauskaite et al., 2024 - Google Patents
276 Outcomes of late probing for congenital nasolacrimal duct obstruction (CNLDO) in children following Covid-19: older children share successful outcomesTamosauskaite et al., 2024
View PDF- Document ID
- 12238074690482338761
- Author
- Tamosauskaite J
- Agrawal A
- Piergentili M
- Geh V
- Publication year
- Publication venue
- BMJ Open Ophthalmology
External Links
Snippet
Nasolacrimal duct probing is standard treatment for CNLDO when conservative management fails. Literature reports indicate lack of consensus on the initial management of CNLDO in older children. We aim to ascertain outcome of delayed probing procedures after …
- 208000025721 COVID-19 0 title abstract description 20
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wei et al. | Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care | |
| Takeuchi et al. | Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement | |
| Keino et al. | Clinical features of uveitis in children and adolescents at a tertiary referral centre in Tokyo | |
| Rittiphairoj et al. | Intravitreal steroids for macular edema in diabetes | |
| Lasave et al. | Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy | |
| Manguinao et al. | A retrospective cohort study of plasma exchange in central nervous system demyelinating events in children | |
| Davies et al. | Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease | |
| Isshiki et al. | Usefulness of low-dose methotrexate monotherapy for treating sarcoidosis | |
| Marchetti et al. | Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement | |
| Tamosauskaite et al. | 276 Outcomes of late probing for congenital nasolacrimal duct obstruction (CNLDO) in children following Covid-19: older children share successful outcomes | |
| Nikiphorou et al. | Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care | |
| Hiyama et al. | Clinical characteristics and efficacy of methotrexate in Japanese patients with noninfectious scleritis | |
| Martín-Begué et al. | Growth hormone treatment and papilledema: a prospective pilot study | |
| Mhéalóid et al. | Alcohol delamination of the corneal epithelium for recurrent corneal erosion syndrome | |
| Figueiredo et al. | Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis | |
| Nguyen et al. | Therapeutic and diagnostic challenges in myasthenia gravis | |
| BIOLOGIC | 278 A RARE PAEDIATRIC CASE OF ANCA-ASSOCIATED VASCULITIS | |
| PAEDIATRIC et al. | Oral Presentations Wednesday 02nd October 2024 | |
| Sasongko et al. | Diabetic retinopathy progression 6 months post‐cataract surgery with intravitreous bevacizumab vs triamcinolone: a secondary analysis of the DiMECAT trial | |
| Lidder et al. | Intraocular Pressure Spike Following Stand-Alone Phacoemulsification in the IRIS® Registry (Intelligent Research in Sight) | |
| Dujardin et al. | 228 Prematurity profile and response to intravitreal ranibizumab in infants treated for retinopathy of prematurity: a case series | |
| Vogel et al. | Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration | |
| Liu et al. | Outcomes and Predictors of Response to Pregabalin for the Treatment of Post-Traumatic Trigeminal Neuropathic Pain Following Neuroablative Procedures: A Retrospective Observational Study | |
| WO2023236967A1 (en) | Method for treating myasthenia gravis with taci-fc fusion protein | |
| Evans et al. | A Case Report of Fedratinib-Associated Uveitis |